MiNK Therapeutics, Inc. (INKT)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

10.72 on 9 Oct 2026

0 buys5 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Net income

$12.49M

Free cash flow

$5.93M

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
4 Jun 2026	Ryan Barbara Director	Sold at will	$19.14K	6.4%
10 Mar 2026	Ryan Barbara Director	Sold at will	$20.02K	6.0%
9 Mar 2026	Ryan Barbara Director	Sold at will	$2.03K	0.9%
2 Mar 2026	Ryan Barbara Director	Sold at will	$1.08K	0.5%
27 Feb 2026	Ryan Barbara Director	Sold at will	$4.34K	1.8%
16 Oct 2023	AGENUS INC 10% owner	Bought	$471.56	0.0%

16out of 100

Profitability 0

Financial strength 20

Growth n/a

Insiders 35

Strongest on insiders (35), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$46.62K

5 sales

Planned sales

under a 10b5-1 plan